AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20357378 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary n‐3 long‐chain polyunsaturated fatty acids (n‐3 LC‐PUFAs)
Number of subjects: 1436
Study 20357378 — intervention group
Group type: COMPARATOR
Intervention: Control group (bottom third of dietary n‐3 LC‐PUFAs)
Number of subjects: 1436
Study 19032733 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT selected based on echocardiographic parameters of myocardial asynchrony
Number of subjects: 16
Study 19032733 — intervention group
Group type: COMPARATOR
Intervention: Control group (historic CRT patients not screened for asynchrony)
Number of subjects: 16
Study 17150108 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproic acid (VPA), mean dose of 850 mg/d for 18 months (range 6-27 months)
Number of subjects: 40
Study 17150108 — intervention group
Group type: COMPARATOR
Intervention: No Valproic acid (Control group)
Number of subjects: 40
Study 14695410 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 g of sucrose
Number of subjects: 12
Study 14695410 — intervention group
Group type: COMPARATOR
Intervention: Placebo (660 ml beverage with artificial sweeteners)
Number of subjects: 12
Study 10821079 — intervention group
Group type: EXPERIMENTAL
Intervention: Econazole nitrate
Number of subjects: 75
Study 10821079 — intervention group
Group type: EXPERIMENTAL
Intervention: Miconazole
Number of subjects: 75
Study 10821079 — intervention group
Group type: EXPERIMENTAL
Intervention: Nystatin
Number of subjects: 75
Study 10821079 — intervention group
Group type: COMPARATOR
Intervention: Econazole nitrate, Miconazole, Nystatin
Number of subjects: 75
Study 8693170 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cells Collection (PBSCC)
Number of subjects: 199
Study 8693170 — intervention group
Group type: COMPARATOR
Intervention: Bone Marrow Collection (BMC)
Number of subjects: 199
Study 1796197 — intervention group
Group type: EXPERIMENTAL
Intervention: morniflumate combined with amoxicillin
Number of subjects: 60
Study 1796197 — intervention group
Group type: COMPARATOR
Intervention: imidazole-2-hydroxybenzoate combined with amoxicillin
Number of subjects: 60
Study 1796197 — intervention group
Group type: COMPARATOR
Intervention: antibiotic therapy alone
Number of subjects: 60
Study 6666232 — intervention group
Group type: EXPERIMENTAL
Intervention: ISDN (3 mg intracoronary)
Number of subjects: 13
Study 6666232 — intervention group
Group type: COMPARATOR
Intervention: ASA (1.0 g intravenous and 100 mg intracoronary)
Number of subjects: 13
Study 6666232 — intervention group
Group type: COMPARATOR
Intervention: ASA (before ISDN administration)
Number of subjects: 13
Study 30803137 — intervention group
Group type: EXPERIMENTAL
Intervention: Amine fluoride/stannous chloride toothpaste
Number of subjects: 240
Study 30803137 — intervention group
Group type: COMPARATOR
Intervention: Monofluorophosphate toothpaste
Number of subjects: 240
Study 28866447 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum tDCS (2-mA, twice-daily sessions for 5-days)
Number of subjects: 25
Study 28866447 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 25
Study 28866447 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham-to-verum crossover in OLE phase
Number of subjects: 25
Study 27228435 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 2029
Study 27228435 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan (within 6h of stroke onset)
Number of subjects: 2029
Study 27228435 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 2029
Study 24687165 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachial-ankle PWV
Number of subjects: 81
Study 24687165 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral-ankle PWV
Number of subjects: 81
Study 24687165 — intervention group
Group type: EXPERIMENTAL
Intervention: Central stiffness (carotid-femoral PWV)
Number of subjects: 81
Study 24687165 — intervention group
Group type: EXPERIMENTAL
Intervention: Central stiffness (heart-femoral PWV)
Number of subjects: 81
Study 22563194 — intervention group
Group type: EXPERIMENTAL
Intervention: LCR35 (n = 25) at a minimum daily dose of 6 × 10(8) colony forming units for 4 weeks
Number of subjects: 50
Study 22563194 — intervention group
Group type: EXPERIMENTAL
Intervention: LCR35 in IBS patients with predominance of diarrhoea
Number of subjects: 50
Study 22563194 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 25) for 4 weeks
Number of subjects: 50
Study 22563194 — intervention group
Group type: COMPARATOR
Intervention: Placebo in IBS patients with predominance of constipation
Number of subjects: 50
Study 22563194 — intervention group
Group type: COMPARATOR
Intervention: Placebo in IBS patients with unsubtyped IBS
Number of subjects: 50
Study 22563194 — intervention group
Group type: EXPERIMENTAL
Intervention: LCR35 in mixed IBS patients
Number of subjects: 50
Study 22563194 — intervention group
Group type: COMPARATOR
Intervention: Placebo in mixed IBS patients
Number of subjects: 50
Study 22563194 — intervention group
Group type: COMPARATOR
Intervention: LCR35 and Placebo in both groups
Number of subjects: 50
Study 20090320 — intervention group
Group type: EXPERIMENTAL
Intervention: Filter-protected CAS
Number of subjects: 30
Study 20090320 — intervention group
Group type: COMPARATOR
Intervention: Unprotected CAS
Number of subjects: 30
Study 17661765 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral chili (5 g daily x 3 days)
Number of subjects: 18
Study 17661765 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral chili with 1-mg intravenous granisetron
Number of subjects: 18
Study 17661765 — intervention group
Group type: COMPARATOR
Intervention: Intravenous granisetron after placebo ingestion
Number of subjects: 18
Study 16310024 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological stressor (administered to 21 patients during the last 90 min of 24-h oesophageal pH monitoring)
Number of subjects: 42
Study 16310024 — intervention group
Group type: COMPARATOR
Intervention: No-stress control condition (administered to the remaining participants)
Number of subjects: 42
Study 16310024 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with greater state anxiety
Number of subjects: 42
Study 11903027 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump surgery
Number of subjects: 281
Study 11903027 — intervention group
Group type: COMPARATOR
Intervention: On-pump surgery
Number of subjects: 281
Study 11903027 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life
Number of subjects: 281
Study 11903027 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke rate
Number of subjects: 281
Study 11903027 — intervention group
Group type: EXPERIMENTAL
Intervention: All-cause mortality
Number of subjects: 281
Study 10203878 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% of the 4-hourly opioid dose
Number of subjects: 33
Study 10203878 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% of the 4-hourly opioid dose
Number of subjects: 33
Study 10203878 — intervention group
Group type: COMPARATOR
Intervention: Both regimens (25% and 50%)
Number of subjects: 33
Study 7780069 — intervention group
Group type: COMPARATOR
Intervention: Meperidine, 25 to 75 mg (n = 10)
Number of subjects: 20
Study 7780069 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium, 0.1 microgram/kg (n = 10), continued as an infusion at 1.0 microgram/kg/min for 4 hours
Number of subjects: 20
Study 2109023 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum levels of TNF
Number of subjects: 70
Study 2109023 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum levels of IL-1 beta
Number of subjects: 70
Study 2109023 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum levels of IFN alpha
Number of subjects: 70
Study 2109023 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum levels of IFN gamma
Number of subjects: 70
Study 2109023 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity of underlying disease
Number of subjects: 70
Study 2109023 — intervention group
Group type: EXPERIMENTAL
Intervention: Age of the patient
Number of subjects: 70
Study 2109023 — intervention group
Group type: EXPERIMENTAL
Intervention: Documentation of infection (nonbacteremic infections vs. bacteremias)
Number of subjects: 70
Study 2109023 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine output
Number of subjects: 70
Study 2109023 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial pH
Number of subjects: 70
Study 2109023 — intervention group
Group type: EXPERIMENTAL
Intervention: Median concentration of TNF in survivors after 10 days
Number of subjects: 70
Study 2109023 — intervention group
Group type: EXPERIMENTAL
Intervention: Median concentration of TNF in nonsurvivors after 10 days
Number of subjects: 70
Study 393465 — intervention group
Group type: EXPERIMENTAL
Intervention: Protacine (150 mg, 3 times daily for 21 days)
Number of subjects: 69
Study 393465 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin (50 mg, 3 times daily for 21 days)
Number of subjects: 69
Study 393465 — intervention group
Group type: EXPERIMENTAL
Intervention: Protacine
Number of subjects: 69
Study 393465 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin
Number of subjects: 69
Study 30649375 — intervention group
Group type: EXPERIMENTAL
Intervention: Micafungin 100mg
Number of subjects: 24
Study 30649375 — intervention group
Group type: EXPERIMENTAL
Intervention: Micafungin 200mg
Number of subjects: 24
Study 30649375 — intervention group
Group type: EXPERIMENTAL
Intervention: Micafungin 300mg
Number of subjects: 24
Study 30649375 — intervention group
Group type: EXPERIMENTAL
Intervention: Loading dose (twice the maintenance dose)
Number of subjects: 24
Study 28816867 — intervention group
Group type: EXPERIMENTAL
Intervention: Air Optix Aqua and Proclear Multifocal Distance and Near (Group 1)
Number of subjects: 35
Study 28816867 — intervention group
Group type: EXPERIMENTAL
Intervention: Air Optix Aqua, Air Optix Multifocal, and PureVision Multifocal (Group 2)
Number of subjects: 35
Study 28816867 — intervention group
Group type: COMPARATOR
Intervention: Single vision control lens
Number of subjects: 35
Study 28816867 — intervention group
Group type: EXPERIMENTAL
Intervention: Center-distance lens
Number of subjects: 35
Study 25557742 — intervention group
Group type: EXPERIMENTAL
Intervention: Type I collagen skin substitute
Number of subjects: 10
Study 25557742 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care wound dressings
Number of subjects: 10
Study 23456790 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound scan arm (TVS)
Number of subjects: 202638
Study 22008746 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG hydrogel spinal sealant
Number of subjects: 158
Study 22008746 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 158
Study 19208047 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic temperature device (1)
Number of subjects: 72
Study 19208047 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal temperature measurement
Number of subjects: 72
Study 19208047 — intervention group
Group type: EXPERIMENTAL
Intervention: Axillary temperature measurement
Number of subjects: 72
Study 19208047 — intervention group
Group type: EXPERIMENTAL
Intervention: Disposable temperature device
Number of subjects: 72
Study 17083638 — intervention group
Group type: EXPERIMENTAL
Intervention: Method one (blood taken directly from cannula hub)
Number of subjects: 1390
Study 17083638 — intervention group
Group type: COMPARATOR
Intervention: Method two (blood taken using an Interlink device through cannula cap)
Number of subjects: 1390
Study 14979213 — intervention group
Group type: EXPERIMENTAL
Intervention: Keyouling oral liquid (high-dosage group)
Number of subjects: 0
Study 14979213 — intervention group
Group type: EXPERIMENTAL
Intervention: Keyouling oral liquid (treatment group)
Number of subjects: 0
Study 14979213 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 11305831 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15 mg clonidine (Group-CL, n=20)
Number of subjects: 60
Study 11305831 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg diazepam (Group-DZ, n=20)
Number of subjects: 60
Study 11305831 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group-P, n=20)
Number of subjects: 60
Study 9220179 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose dopamine (2 micrograms/kg/min)
Number of subjects: 20
Study 9220179 — intervention group
Group type: COMPARATOR
Intervention: Intravenous bumetanide (1 mg b.i.d.) alone
Number of subjects: 20
Study 11767421 — intervention group
Group type: EXPERIMENTAL
Intervention: Netilmicin 2 mg kg‐1
Number of subjects: 50
Study 11767421 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime 20 mg kg‐1
Number of subjects: 50
Study 11767421 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole 7.5 mg kg‐1
Number of subjects: 50
Study 11767421 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime 20 mg kg‐1 and Metronidazole 7.5 mg kg‐1
Number of subjects: 50
Study 11767421 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 3329738 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (Inderal‐LA)
Number of subjects: 95
Study 3329738 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 3329738 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 95
Study 29570588 — intervention group
Group type: EXPERIMENTAL
Intervention: Early initiation of parenteral nutrition
Number of subjects: 37
Study 29570588 — intervention group
Group type: COMPARATOR
Intervention: Late initiation of parenteral nutrition
Number of subjects: 37
Study 25768376 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg/kg for intubation followed by sugammadex 4.0 mg/kg for reversal.
Number of subjects: 150
Study 25768376 — intervention group
Group type: COMPARATOR
Intervention: Succinylcholine 1.0 mg/kg for intubation with spontaneous recovery.
Number of subjects: 150
Study 25768376 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium-sugammadex group
Number of subjects: 150
Study 25768376 — intervention group
Group type: COMPARATOR
Intervention: Succinylcholine group
Number of subjects: 150
Study 24619151 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 978
Study 24619151 — intervention group
Group type: COMPARATOR
Intervention: Diabetes support and education (Control)
Number of subjects: 978
Study 22672501 — intervention group
Group type: EXPERIMENTAL
Intervention: vildagliptin/metformin
Number of subjects: 60
Study 22672501 — intervention group
Group type: COMPARATOR
Intervention: metformin only
Number of subjects: 60
Study 19897503 — intervention group
Group type: EXPERIMENTAL
Intervention: Paced RV-LV interlead electrical delay during RV and LV pacing
Number of subjects: 52
Study 19897503 — intervention group
Group type: EXPERIMENTAL
Intervention: DeltapRV-LV interlead electrical delay
Number of subjects: 52
Study 19897503 — intervention group
Group type: COMPARATOR
Intervention: RV-LV interlead electrical delay during spontaneous rhythm
Number of subjects: 52
Study 18053311 — intervention group
Group type: EXPERIMENTAL
Intervention: Three meals per day (breakfast, lunch, dinner)
Number of subjects: 14
Study 18053311 — intervention group
Group type: COMPARATOR
Intervention: Two meals per day (breakfast, dinner)
Number of subjects: 14
Study 17121765 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromelain 800 mg/day
Number of subjects: 47
Study 17121765 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 12933427 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 0.75 micro g/kg in bolus, followed by continuous infusion of 0.075 micro g x kg(‐1) x min(‐1) (Group L)
Number of subjects: 24
Study 12933427 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 1.5 micro g/kg in bolus, followed by continuous infusion of 0.15 micro g x kg(‐1) x min(‐1) (Group H)
Number of subjects: 24
Study 11529283 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol (twice daily 24 microg by Turbuhaler)
Number of subjects: 19
Study 11529283 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (twice daily 100 microg by Diskhaler)
Number of subjects: 19
Study 11529283 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 9170488 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate oxytocin induction
Number of subjects: 7493
Study 9170488 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal prostaglandins
Number of subjects: 7493
Study 9170488 — intervention group
Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 7493
Study 8220396 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid (protein) capsules
Number of subjects: 28
Study 8220396 — intervention group
Group type: COMPARATOR
Intervention: Lactose (placebo) capsules
Number of subjects: 28
Study 8220396 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Amino acid and Lactose)
Number of subjects: 28
Study 3327931 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (25 mg twice daily)
Number of subjects: 152
Study 3327931 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ, 12.5 mg twice daily)
Number of subjects: 152
Study 3327931 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study 31389672 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.02% PCA lotion for 8 weeks
Number of subjects: 22
Study 31389672 — intervention group
Group type: COMPARATOR
Intervention: Placebo lotion for 8 weeks
Number of subjects: 22
Study 30606315 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal isoniazid preventive therapy (IPT)
Number of subjects: 0
Study 30606315 — intervention group
Group type: EXPERIMENTAL
Intervention: QuantiFERON®‐TB Gold In‐Tube (QGIT) directed IPT
Number of subjects: 0
Study 30606315 — intervention group
Group type: COMPARATOR
Intervention: TST-directed IPT
Number of subjects: 0
Study 28486342 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive-based intervention (n=51)
Number of subjects: 99
Study 28486342 — intervention group
Group type: COMPARATOR
Intervention: No incentive (n=48)
Number of subjects: 99
Study 25680623 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-drug regimen (irinotecan, oxaliplatin, tegafur-uracil with leucovorin and cetuximab)
Number of subjects: 48
Study 24156558 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) intervention
Number of subjects: 54
Study 24156558 — intervention group
Group type: COMPARATOR
Intervention: Self-Directed Intervention (SDI) (control)
Number of subjects: 54
Study 20878265 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 24
Study 20878265 — intervention group
Group type: COMPARATOR
Intervention: Barbiturates
Number of subjects: 24
Study 18510819 — intervention group
Group type: COMPARATOR
Intervention: Taste-masked quinine sulphate pellets (600 mg single dose for adults; 10-12.5 mg/kg every 8 hours for 7 days for children)
Number of subjects: 56
Study 18510819 — intervention group
Group type: COMPARATOR
Intervention: Commercially available tablets (control for adults)
Number of subjects: 56
Study 16918261 — intervention group
Group type: EXPERIMENTAL
Intervention: Epratuzumab (humanised anti-CD22 antibody)
Number of subjects: 0
Study 12665979 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal velocity (V(opt): 116.6 rpm)
Number of subjects: 13
Study 12665979 — intervention group
Group type: COMPARATOR
Intervention: 50% Optimal velocity (0.5 V(opt): 60.6 rpm)
Number of subjects: 13
Study 10740436 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg orally twice daily
Number of subjects: 172
Study 10740436 — intervention group
Group type: COMPARATOR
Intervention: Pivampicillin 700 mg orally twice daily
Number of subjects: 172
Study 8922570 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin estolate (40 mg/kg/d in two divided doses for five days)
Number of subjects: 227
Study 8922570 — intervention group
Group type: COMPARATOR
Intervention: Penicillin V (30 mg/kg/d in three divided doses for ten days)
Number of subjects: 227
Study 8922570 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin estolate
Number of subjects: 227
Study 8922570 — intervention group
Group type: COMPARATOR
Intervention: Penicillin V
Number of subjects: 227
Study 8922570 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin estolate and Penicillin V
Number of subjects: 227
Study 29390048 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate-dose cytarabine (1000 mg/m2 twice daily on days 1, 3, 5, 7) plus mitoxantrone (10 mg/m2 days 1-3) (IMA)
Number of subjects: 485
Study 29390048 — intervention group
Group type: COMPARATOR
Intervention: Standard induction therapy with cytarabine (100 mg/m2 continuously days 1-7) plus daunorubicin (45 mg/m2 days 3-5) (DA)
Number of subjects: 485
Study 29390048 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate-dose cytarabine plus mitoxantrone (IMA)
Number of subjects: 485
Study 29390048 — intervention group
Group type: COMPARATOR
Intervention: Standard induction therapy with cytarabine plus daunorubicin (DA)
Number of subjects: 485
Study 29390048 — intervention group
Group type: EXPERIMENTAL
Intervention: Both IMA and DA
Number of subjects: 485
Study 28453759 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukapheresis treatment with CCL25 column
Number of subjects: 22
Study 28453759 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 22
Study 26222774 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR <60 ml/min/1.73 m2 and elevated OPG
Number of subjects: 1292
Study 26222774 — intervention group
Group type: COMPARATOR
Intervention: eGFR ≥60 ml/min/1.73 m2 and low OPG
Number of subjects: 1292
Study 26222774 — intervention group
Group type: EXPERIMENTAL
Intervention: elevated OPG and stage III CKD
Number of subjects: 1292
Study 23690357 — intervention group
Group type: EXPERIMENTAL
Intervention: High-viscosity Glass-ionomer Cement (GIC) group
Number of subjects: 2640
Study 23690357 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride Resin-based group (fluoride-RB)
Number of subjects: 2640
Study 23690357 — intervention group
Group type: COMPARATOR
Intervention: No-fluoride Resin-based group (RB)
Number of subjects: 2640
Study 21384187 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal-hybrid cholecystectomy
Number of subjects: 51
Study 21384187 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-port cholecystectomy
Number of subjects: 51
Study 21384187 — intervention group
Group type: COMPARATOR
Intervention: Four-trocar laparoscopic cholecystectomy
Number of subjects: 51
Study 18805677 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRI treatment
Number of subjects: 31